Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Dunn, D. Pillay (2007)
UK HIV drug resistance database: background and recent outputs.Journal of HIV therapy, 12 4
P. Cane (2005)
Stability of transmitted drug-resistant HIV-1 speciesCurrent Opinion in Infectious Diseases, 18
Koval Koval, Dykes Dykes, Wang Wang, Demeter Demeter (2006)
Relative replication fitness of efavirenz‐resistant mutants of HIV‐1correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N+L100I by the nucleoside resistance mutation L74V, 353
A. Nicoll, O. Gill, Catherine Peckham, A. Ades, John Parry, Philip Mortimer, David Goldberg, Ahilya Noone, Diane Bennett, Mike Catchpole (2000)
The public health applications of unlinked anonymous seroprevalence monitoring for HIV in the United Kingdom.International journal of epidemiology, 29 1
(2008)
on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy
(2008)
UK HIV Drug Resistance Database annual report 2007 / 08
S. Fidler, J. Frater, J. Clarke, J. Weber (2001)
HIV-1 drug resistance in primary infections in the UKBMJ : British Medical Journal, 323
J. Tang, D. Pillay (2004)
Transmission of HIV-1 drug resistance.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 30 1
Jeffrey Johnson, Jin-fen Li, Xierong Wei, Jonathan Lipscomb, D. Bennett, Ashley Brant, M. Cong, T. Spira, R. Shafer, W. Heneine (2007)
Simple PCR Assays Improve the Sensitivity of HIV-1 Subtype B Drug Resistance Testing and Allow Linking of Resistance MutationsPLoS ONE, 2
Gary Murphy, Andre Charlett, Alison Brown, O. Gill, John Parry (2004)
Is HIV incidence increasing in homo/bisexual men attending GUM clinics in England, Wales and Northern Ireland?Communicable disease and public health, 7 1
R. Gandhi, A. Wurcel, E. Rosenberg, M. Johnston, N. Hellmann, M. Bates, M. Hirsch, B. Walker (2003)
Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 37 12
(2007)
UK HIV Drug Resistance Database annual report
K. Metzner, S. Giulieri, Stefanie Knoepfel, P. Rauch, P. Burgisser, S. Yerly, H. Günthard, M. Cavassini (2009)
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 48 2
C. Koval, C. Dykes, Jiong Wang, L. Demeter (2006)
Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.Virology, 353 1
Bennett Bennett, Camacho Camacho, Otelea Otelea (2009)
Drug resistance mutations for surveillance of transmitted HIV‐1 drug‐resistance2009 update, 4
R. Paredes, I. Cheng, D. Kuritzkes, R. Tuomala (2007)
High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998–2004AIDS, 21
D. Pao, U. Andrady, J. Clarke, G. Dean, S. Drake, M. Fisher, Tanya Green, Siva Kumar, M. Murphy, A. Tang, Stephen Taylor, D. White, G. Underhill, D. Pillay, P. Cane (2004)
Long-Term Persistence of Primary Genotypic Resistance After HIV-1 SeroconversionJAIDS Journal of Acquired Immune Deficiency Syndromes, 37
D. Turner (2011)
Does the M184V resistance mutation in reverse transcriptase reduce HIV transmission? *HIV Medicine, 12
Denise Kothe, Robert Byers, Samuel Caudill, Glen Satten, Robert Janssen, W. Hannon, Joanne Mei (2003)
Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence.Journal of acquired immune deficiency syndromes, 33 5
P. Cane, I. Chrystie, D. Dunn, B. Evans, A. Geretti, H. Green, A. Phillips, D. Pillay, K. Porter, A. Pozniak, C. Sabin, E. Smit, J. Weber, M. Zuckerman (2005)
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational studyBMJ : British Medical Journal, 331
B. Gazzard (2005)
British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008HIV Medicine, 9
D. Bennett, R. Camacho, D. Otelea, D. Kuritzkes, H. Fleury, M. Kiuchi, W. Heneine, R. Kantor, M. Jordan, J. Schapiro, A. Vandamme, P. Sandstrom, C. Boucher, D. Vijver, Soo-Yon Rhee, Tommy Liu, D. Pillay, R. Shafer (2009)
Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 UpdatePLoS ONE, 4
Cane (2005)
Time trends in primary resistance to HIV drugs in the United Kingdommulticentre observational study, 331
Objectives The aim of the study was to estimate the levels of transmitted drug resistance (TDR) in HIV‐1 using very sensitive assays to detect minority drug‐resistant populations. Methods We tested unlinked anonymous serum specimens from sexual health clinic attendees, who had not received an HIV diagnosis at the time of sampling, by both standard genotyping and using minority detection assays. Results By standard genotyping, 21 of 165 specimens (12.7%) showed evidence of drug resistance, while, using a combination of standard genotyping and minority mutation assays targeting three commonly observed drug resistance mutations which cause high‐level resistance to commonly prescribed first‐line antiretroviral therapy (ART), this rose to 32 of 165 (19.4%). This increase of 45% in drug resistance levels (95% confidence interval (CI) 15.2–83.7%; P=0.002) was statistically significant. Almost all of this increase was accounted for by additional detections of the M184V mutation. Conclusions Future surveillance studies of TDR in the United Kingdom should consider combining standard genotyping and minority‐specific assays to provide more accurate estimates, particularly when using specimens collected from chronic HIV infections in which TDR variants may have declined to low levels.
Hiv Medicine – Wiley
Published: Apr 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.